New study tests Self-Management as a Drug-Free fix for hip pain
NCT ID NCT06297148
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a self-management program led by a physiotherapist can reduce pain and improve function in people with greater trochanteric pain syndrome (chronic hip pain). 110 adults aged 18-70 with hip pain for over 3 months will be randomly assigned to either the self-management program or usual care. The program includes education, goal-setting, and activity planning over 3-5 sessions, with follow-ups at 3, 6, and 12 months.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- self-management program (education and exercise with a physiotherapist)
- What this could lead to
- If it works, this could offer an effective, low-cost way to manage chronic hip pain without surgery or injections.
- What could go wrong
- This is a small, single-center trial with 110 participants, so results may not apply to everyone. The self-management program may not be better than usual care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 110 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2024
- Expected to finish
-
Oct 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Participants between 18 and 70 years of age * History of lateral hip pain \> 3 months * Reported average pain intensity the last week ≥ 3 on a numeric rating scale * Lateral hip pain is the main complaint * Pain on palpation of the greater trochanter region * In addition, lateral hip pain on at least one of the following tests: * Single leg stance test: standing 30 seconds on the affected leg * FADER: passive stretch/compression of gluteus medius/minimus * FADER-R: static muscle test with resistance to internal hip rotation * ADD: passive stretch to hip adduction in sidelying * ADD-R: resisted hip abduction in sidelying * FABER (Patrick's) test A positive test is defined as a spontaneous reproduction of the participant's lateral hip pain. In participants with bilateral lateral hip pain, the worst hip will be included, and the presence of bilateral pain will be documented. Exclusion Criteria: * Significant back pain causing referred pain to the lateral hip * Clinical signs of radiculopathy * Symptomatic osteoarthritis * Other hip joint pathologies * History of trauma or surgery on the affected side * Pregnancy or post-partum pelvic pain (under 12 months since birth) * Active cancer * Not able to write, read, and comprehend Norwegian (without the use of an interpreter)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Gluteal tendinopathy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Oslo University Hospital, Ullevål
Oslo, 0450, Norway
More trials for these conditions
Other studies related to the condition(s) this trial covers.